Project 4: """"""""Molecular and cellular action of HLA class II molecules, the major genetic risk factors for VL"""""""" The studies will build on observations made during the current TMRC, in collaboration with Phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2), that HLA DR_DQ class 11 region contains the major genetic risk factor for visceral leishmaniasis in India (and Brazil).
Four specific aims are proposed: 1. To determine transcriptional signatures in whole blood and/or splenic aspirates from active and past cases, and Quantiferon and/or antibody positive asymptomatic infected donors (Project 1), carrying risk versus protective HLA DRB1 allele groups. 2. To determine at mRNA and protein levels ex vivo, and following stimulation/infection of cells in vitro, whether cis-acting regulatory polymorphisms are functional correlates of risk and protective HLA DRB1 allele groups. 3. To purify, and identify using mass spectrometry, naturally processed leishmanial peptides from EBV transformed B cells prepared from HLA DRB1*13/*14 versus HLA DRB1*15 donors stimulated with whole crude parasite lysate prepared from a local Indian strain of L. donovani, compare with in silico predictions of epitopes and binding affinity, and develop a strategy to subvert the immune response by vaccination 4. To validate results of aim 3 by measuring antigen presenting cell function and immune response to naturally processed and predicted peptide epitopes in exposed individuals, including active and past cases, and asymptomatic infected donors.
Project 4. These studies will contribute to understanding of the molecular and cellular basis of HLA class genes as the major genetic risk factors for disease, and have implications for therapeutics and vaccine design and delivery.
|Singh, Om Prakash; Hasker, Epco; Boelaert, Marleen et al. (2016) Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis 16:e304-e309|
|Sundar, Shyam; Singh, Anup (2016) Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis 3:98-109|
|Singh, Neetu; Kumar, Rajiv; Engwerda, Christian et al. (2016) Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-? production by spleen cells from human visceral leishmaniasis patients. Cytokine 85:184-90|
|Sharma, Smriti; Davis, Richard E; Srivastva, Shweta et al. (2016) A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis. J Infect Dis 214:1531-1538|
|Singh, Om Prakash; Singh, Bhawana; Chakravarty, Jaya et al. (2016) Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty 5:19|
|Faleiro, Rebecca J; Kumar, Rajiv; Bunn, Patrick T et al. (2016) Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS Negl Trop Dis 10:e0004415|
|Sudarshan, Medhavi; Singh, Toolika; Singh, Bhawana et al. (2016) Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. Microbes Infect 18:369-72|
|Montes de Oca, Marcela; Kumar, Rajiv; de Labastida Rivera, Fabian et al. (2016) Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. PLoS Pathog 12:e1005398|
|Ghosh, Prakash; Hasnain, Md Golam; Ghosh, Debashis et al. (2015) A comparative evaluation of the performance of commercially available rapid immunochromatographic tests for the diagnosis of visceral leishmaniasis in Bangladesh. Parasit Vectors 8:331|
|Sudarshan, Medhavi; Singh, Toolika; Chakravarty, Jaya et al. (2015) A Correlative Study of Splenic Parasite Score and Peripheral Blood Parasite Load Estimation by Quantitative PCR in Visceral Leishmaniasis. J Clin Microbiol 53:3905-7|
Showing the most recent 10 out of 79 publications